Study Finds E-Cigarettes Significantly Aid Smoking Cessation

Dec.29.2022
Study Finds E-Cigarettes Significantly Aid Smoking Cessation
A French study found that using e-cigarettes is significantly related to quitting smoking, while Nicotine Replacement Therapy is not.

French smoking cessation experts have long been encouraging smokers to switch to e-cigarettes, with nearly two-thirds of e-cigarette users hoping to quit smoking.


A study abstract published in the Journal of Preventive Medicine found a significant correlation between using e-cigarettes and quitting smoking, while the use of nicotine replacement therapy (NRT) showed a negative correlation with quitting smoking.


Most individuals have likely been able to successfully overcome their dependence on nicotine, but they did not utilize e-cigarettes, nicotine replacement therapies, or other smoking cessation products.


Eight researchers examined the 2017 French Health Survey data, which involved 2,783 adult smokers who had smoked for at least six months and had attempted to quit smoking within the four years prior to the survey and had abstained for at least six months from their last quitting attempt.


Of the 2,783 individuals included in the study, the majority - 61.7% or 1,716 - attempted to quit smoking independently without the use of e-cigarettes, nicotine replacement therapy (NRT), or any other smoking cessation products.


For about four years, Nicotine Replacement Therapy (NRT) has been the cornerstone of smoking cessation policies in developed countries. The major news from this study is that those who attempt to quit smoking without the help of NRT have a 27% greater likelihood of failing to stay smoke-free for six months, a 38% greater likelihood of failing to remain smoke-free for a year, and a 43% greater likelihood of failing to remain smoke-free for two years compared to those who use NRT to quit smoking.


On the contrary, the study titled "Use of Smoking Cessation Aids and Likelihood of Quitting: A Study Based on the French Population" declares that the majority of electronic cigarette users who remain addicted and dependent on nicotine are losers, despite only 15% of the 2,783 surveyed smokers successfully quitting with electronic cigarettes.


This is the second 2022 European study to find that NRT reduces smoking cessation success. Mirroring a UK study in July, the unadjusted odds of quitting through OTC NRT were found to be 43% lower within a year compared to quitting independently.


As early as 1972, the tobacco industry was aware that nicotine was a necessary component of smoking. It appears that researchers focused on smoking cessation were not yet established at that time.


More than 100 studies in 2022 have explored the risks of nicotine and electronic cigarettes. However, despite this, the scientific community still knows very little about the long-term risks of most e-cigarettes in the absence of long-term data.


As shown by research from France, is drug addiction a solution? If so, what is the cure? More nicotine?


According to Professor Simon Chapman, author of the book "Massive Misconceptions: Fighting the Anti-Smoking Movement" published in 2022, and co-author of a 2010 paper, the biggest overlooked aspect in smoking cessation research is the lack of scientific understanding of how to quit smoking without assistance, as most smokers attempt to quit without help.


According to research findings on PubMed and other platforms, researchers studying smoking cessation have not yet shared the key factors that enabled most smokers in a French study to successfully break free from nicotine's hold on their minds and lives.


Will 2023 be the year when hundreds of smoking cessation experts are finally able to explain how most smokers can successfully quit? Ultimately, empathy will help them understand that the biggest danger from tobacco isn't the diseases that may surface years or decades down the line. It's a chemical enslavement, the two-and-a-half-hour half-life of nicotine, and how each and every waking hour is spent.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
Gallery | InterTabac 2026 Opens as VAPORESSO, SKE, GREENTANK, GEEK BAR and Other Brands Take the Floor
Gallery | InterTabac 2026 Opens as VAPORESSO, SKE, GREENTANK, GEEK BAR and Other Brands Take the Floor
InterTabac 2026 opened in Dortmund, Germany, on September 15 alongside NUBIZ and InterSupply. According to the latest figures released by the organizer, the three trade shows bring together around 750 exhibitors from 64 countries. On site, 2Firsts observed vaping and related brands including VAPORESSO, DOJO, SKE, GREENTANK, GEEK BAR, HQD and ELUX.
Special Report
Sep.15
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27